Tofacitinib in juvenile idiopathic arthritis

Affiliations

¹ MRC Integrative Epidemiology Unit and School of Population Health Sciences, University of Bristol, Bristol BS2 8BJ, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
² School of Translation Health Sciences, University of Bristol, Bristol BS2 8BJ, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK. Electronic address: a.ramanan@bristol.ac.uk.

Comment

Sarah L N Clarke et al. Lancet. 2021.

. 2021 Nov 27;398(10315):1943-1945.

doi: 10.1016/S0140-6736(21)01444-6. Epub 2021 Nov 9.

¹ MRC Integrative Epidemiology Unit and School of Population Health Sciences, University of Bristol, Bristol BS2 8BJ, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
² School of Translation Health Sciences, University of Bristol, Bristol BS2 8BJ, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK. Electronic address: a.ramanan@bristol.ac.uk.

No abstract available

Comment on

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Ruperto N, et al. Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9. Lancet. 2021. PMID: 34767764 Clinical Trial.